Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has approved a new dose strength for Alpharma's pain drug Kadian, which is intended to offer patients more choices in managing their pain.
Subscribe to our email newsletter
The company expects to launch the new 10mg strength capsule in 2007. Kadian is Alpharma’s branded extended release morphine sulfate product and is currently marketed in 20mg, 30mg, 50mg, 60mg, 80mg, 100mg and 200mg dosage strengths.
“We are pleased to be able to offer a wide array of Kadian dosage strengths to physicians and their patients. We will now have the broadest range of dosage strengths in the long-acting opioid market,” said Dr Ronald Warner, president of Alpharma’s pharmaceuticals business.